At the crossroads of consumer fear and medical authority, there is a land ripe with opportunities for specialty practitioners and the drug companies that love them. “Prediabetes” is a mischievous little diagnosis that remains unrecognized by most international diabetes organizations, but in the United States the number of people with the diagnosis grows at a rate similar to the growth of the bank accounts of the American Diabetes Association’s resident experts. This Science article provides the minimum-effective dose of rage against the medical-pharmaceutical complex.
About the Author
Charles Piller is an investigative journalist for Science. He’s also written about public health for STAT, the Los Angeles Times and The Sacramento Bee.